Shares in Nanosynth Group have been on a tear over the last week, following interest on its work in the field of protective masks.
Now that the global population is – slowly – getting vaccinated, investors are turning to look for opportunities among companies that have long term solutions to the virus.
Nanosynth recently announced that it had entered into an agreement with a firm in India for the sale of 250,000 Pro-Larva anti-viral face masks. These makes have been shown to actually be able to kill the virus when it lands on them, making them far more useful for medical professionals.
Nanosynth Group plc (LON:NNN) is focused on the synthesis and application of nanoparticles. The group uses a patented process developed by Dr Cave at Nottingham Trent University. It has three subsidiaries; Pharm 2 Farm Ltd, nanosynth ltd and Cloudveil.